Malaria & Lariam (mefloquine) – latest guidelines
Summary of information received from MHRA – Medicines & Healthcare Products Regulatory Authority. Although the risk of neuropsychiatric side effects with mefloquine (Lariam) is well-established, a recent review of the prescribing information has led to strengthened warnings and new measures to help minimise risks. To minimise the risk of
February 16, 2014
No Comments